Summary: Guest: Brad McGregor, MD <br> <p><span xml:lang="EN-US" data-contrast="auto">HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
